Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus vedolizumab in adults with moderate to severe ulcerative colitis
NL-OMON60910Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in autoimmune colitis comparing Risankizumab with Vedolizumab (2 arms). Primary endpoint: Endoscopic improvement at Week 48. Started Aug 2025; status: active, not recruiting.
02
Drugs
risankizumabvedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60910.